论文部分内容阅读
目的了解浙江省柯萨奇病毒A16(CA16)VP1基因特征及其变迁规律并预测VP1蛋白上B细胞抗原表位。方法在Gen Bank检索并下载35个浙江省CA16流行株及69个已知基因型CA16参考株的VP1基因序列,使用MEGA 6.0软件进行比对分析和构建种系进化树,确定浙江省CA16流行株的基因型,并分析VP1核苷酸和氨基酸同源性及氨基酸变异;运用DNA Star中的Protean模块预测VP1上可能的线性B淋巴细胞抗原表位。结果浙江省CA16病毒基因型为B1基因型(34株)和A基因型(1株)。B1型中以B1b亚型(24株)占绝对优势,其次为B1a亚型(10株)。浙江省CA16流行株VP1核苷酸和氨基酸同源性分别为75.5%~100%和89.5%~100%;VP1区氨基酸序列高度保守,但也存在部分变异。VP1中可能的B细胞抗原表位(氨基酸肽段)有13个,分别为10-20、30-38、57-62、73-79、98-106、118-123、159-168、173-177、184-189、240-246、265-273、274-284和289-295。结论浙江省CA16流行株存在A、B1 2个基因型,B1b和B1a为主要基因型,其VP1区氨基酸变异程度较低,VP1中13个预测的B细胞抗原表位可为CA16疫苗的研制提供科学依据。
Objective To investigate the characteristics and changes of VP1 gene of Coxsackievirus A16 (CA16) in Zhejiang Province and predict the B cell epitopes on VP1 protein. Methods The VP1 gene sequences of 35 CA16 strains of Zhejiang Province and 69 CA16 reference strains of known genotypes were searched and downloaded from Gen Bank. The MEGA 6.0 software was used to compare and construct the phylogenetic tree. The genotypes of VP1 were analyzed, and the nucleotide and amino acid homology and amino acid variation of VP1 were analyzed. The possible linear B lymphocyte epitopes on VP1 were predicted by the Protean module in DNA Star. Results The genotypes of CA16 virus in Zhejiang Province were B1 genotype (34 strains) and A genotype (1 strain). B1 type B1b subtype (24 strains) accounted for the absolute advantage, followed by B1a subtype (10 strains). The nucleotide and amino acid homology of VP1 in Zhejiang province was 75.5% -100% and 89.5% -100%, respectively. The amino acid sequence of VP1 was highly conserved, but there were some variations. There are 13 potential B cell epitopes (amino acid peptides) in VP1, which are 10-20, 30-38, 57-62, 73-79, 98-106, 118-123, 159-168, 173- 177, 184-189, 240-246, 265-273, 274-284 and 289-295. Conclusion There are two genotypes A and B1 in CA16 epidemic strains in Zhejiang Province, B1b and B1a are the major genotypes, and the degree of amino acid variation in VP1 region is low. Thirteen predicted B cell epitopes in VP1 can be provided for the development of CA16 vaccine Scientific basis.